INO—…what [is] the point of producing therapeutic proteins and antibodies endogenously? Why bother, especially for therapeutic proteins?
As far as I can tell, the premise is the potential availability of dMAbs in parts of the world where conventionally produced antibody drugs are unaffordable.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.